Financial reports
10-Q
2024 Q3
Quarterly report
6 Nov 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
10-Q
2024 Q1
Quarterly report
9 May 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
Current reports
8-K
Departure of Directors or Certain Officers
24 Jan 25
8-K
Entry into a Material Definitive Agreement
17 Dec 24
8-K
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
26 Nov 24
8-K
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
6 Nov 24
8-K
Soleno Therapeutics Announces Updates to its Board of Directors
15 Aug 24
8-K
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
7 Aug 24
8-K
Entry into a Material Definitive Agreement
19 Jul 24
8-K
Departure of Directors or Certain Officers
19 Jul 24
8-K
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi
28 Jun 24
8-K
Entry into a Material Definitive Agreement
20 Jun 24
Registration and prospectus
S-8
Registration of securities for employees
7 Aug 24
424B5
Prospectus supplement for primary offering
19 Jul 24
424B5
Prospectus supplement for primary offering
6 May 24
424B5
Prospectus supplement for primary offering
2 May 24
S-8
Registration of securities for employees
31 Jan 24
S-8
Registration of securities for employees
17 Jan 24
S-3ASR
Automatic shelf registration
2 Jan 24
S-3
Shelf registration
20 Oct 23
D
$59.99 mm in equity / options / securities to be acquired, sold $59.99 mm, 14 investors
4 Oct 23
424B5
Prospectus supplement for primary offering
29 Sep 23
Proxies
DEF 14A
Definitive proxy
22 Apr 24
DEF 14A
Definitive proxy
14 Apr 23
PRE 14A
Preliminary proxy
4 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 21
DEF 14A
Definitive proxy
19 Oct 20
PRE 14A
Preliminary proxy
2 Oct 20
DEF 14A
Definitive proxy
20 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 19
Other
EFFECT
Notice of effectiveness
1 Nov 23
CORRESP
Correspondence with SEC
27 Oct 23
UPLOAD
Letter from SEC
27 Oct 23
EFFECT
Notice of effectiveness
3 Aug 23
CORRESP
Correspondence with SEC
31 Jul 23
UPLOAD
Letter from SEC
28 Jul 23
EFFECT
Notice of effectiveness
10 Feb 21
CORRESP
Correspondence with SEC
5 Feb 21
CORRESP
Correspondence with SEC
2 Feb 21
UPLOAD
Letter from SEC
28 Jan 21
Ownership
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 25
SC 13G/A
JANUS HENDERSON GROUP PLC
14 Feb 25
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
12 Feb 25
SC 13G/A
BlackRock, Inc.
5 Feb 25
4
Kristen Yen
23 Jan 25
4
Meredith Manning
23 Jan 25
4
James H Mackaness
23 Jan 25
4
Michael F. Huang
23 Jan 25
4
Patricia C Hirano
23 Jan 25
4
Bhatnagar Anish
23 Jan 25